After Takeda's Phase 3 Topline Study Results For Soticlestat, Ovid Says It Will Prioritize And Pursue Its Programs With Financial Discipline And Expects Its Cash Runway To Last Into The First Half Of 2026
After Takeda's Phase 3 Topline Study Results For Soticlestat, Ovid Says It Will Prioritize And Pursue Its Programs With Financial Discipline And Expects Its Cash Runway To Last Into The First Half Of 2026
在武田製藥關於Soticlestat的第3階段頂線研究結果後，Ovid表示將以財務紀律優先並推進自己的項目，並期望其現金儲備可支持至2026年上半年。
After Takeda's Phase 3 Topline Study Results For Soticlestat, Ovid Says It Will Prioritize And Pursue Its Programs With Financial Discipline And Expects Its Cash Runway To Last Into The First Half Of 2026
在武田製藥關於Soticlestat的第3階段頂線研究結果後，Ovid表示將以財務紀律優先並推進自己的項目，並期望其現金儲備可支持至2026年上半年。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。